Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology NASDAQ
$759.86
$-5.07 (-0.66%)
Open: $758.90 | High: $762.70 | Low: $747.82 | Prev Close: $764.93
Market Cap: $78.95B
Volume: 562K | Avg: 821K
Last updated: March 09, 2026 at 02:04 AMInvestment Rating
Buy
Overall Score: 80/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 625
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 18.31 |
| P/B Ratio | 2.50 |
| P/S Ratio | 5.50 |
| EPS | $41.49 |
| Beta | 0.40 |
| Shares Outstanding | 103.90M |
| 52-Week High | $821.11 |
| 52-Week Low | $476.49 |
| SMA 50 | $771.72 |
| SMA 200 | $642.39 |
| Dividend Yield | 0.47% |
| Annual Dividend | $3.58 |
| Next Earnings | April 29, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 85.4% |
| Operating Margin | 24.9% |
| Net Margin | 31.4% |
| ROE | 14.8% |
| ROA | 11.1% |
| Debt/Equity | 0.09 |
| Current Ratio | 4.13 |
| Quick Ratio | 3.39 |
Balance Sheet
| Total Assets | $40.56B |
| Total Liabilities | $9.30B |
| Total Equity | $31.26B |
|
|
|
| Cash | $3.12B |
| Total Debt | $2.71B |
| Net Debt | $-412,200,000 |
Income Statement
| Revenue | $14.34B |
| Gross Profit | $12.24B |
| Operating Income | $3.58B |
| Net Income | $4.50B |
|
|
|
| EBITDA | $5.82B |
| Revenue/Share | $139.39 |
Cash Flow
| Operating CF | $4.98B |
| CapEx | $898.40M |
| Free Cash Flow | $4.08B |
|
|
|
| Book Value/Share | $303.76 |
| Tangible Book/Share | $291.54 |
| Equity/Share | $303.76 |
Technical Indicators
| RSI (14) | 32.58 Neutral |
| MACD |
0.62
Signal: 3.46
|
| Volatility | 22.01% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | +27.38% |
| Sharpe Ratio | 0.77 Fair |
| Volatility (Ann.) | 38.05% Moderate |
| REGN (1Y) | +27.38% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | +14.34% |
Sector Comparison (Healthcare)
| Metric | REGN | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 18.31 | 27.84 | 26% |
| P/B Ratio | 2.5 | -19.57 | 42% |
| ROE (%) | 14.83% | -9.57% | 59% |
| Net Margin (%) | 31.41% | 8.89% | 94% |
| Stock Score | 625 | 542.0 | 87% |
| 1Y Return (%) | +27.38 % | +7.77 % | 77% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REGN | $759.86 | $771.47 | $771.50 | $776.34 | $771.28 | $642.28 | 32.58 | 0.62 | 22.01% | 84756 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the REGN stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| REGN | In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making | Neutral | fool.com | Read More |
| REGN | Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript | Neutral | seekingalpha.com | Read More |
| REGN | Regeneron: Fairly Valued Now After A Stellar Upswing | Neutral | seekingalpha.com | Read More |
| REGN | Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment | Neutral | globenewswire.com | Read More |
| REGN | Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment | Neutral | globenewswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for REGN
Company Information
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
| CEO | Leonard S. Schleifer |
| Employees | 15158 |
| Country | US |
| IPO Date | 1991-04-02 |
| Exchange | NASDAQ |
| Website | https://www.regeneron.com |
| Sector | Healthcare |
| Industry | Biotechnology |
Similar Stocks (Healthcare - Biotechnology)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category